[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353990-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353990-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","use-of-in-vitro-co-culture-models-to-inform-bacterial-engineering-for-the-treatment-of-solid-tumours","Use of in vitro co-culture models to inform bacterial engineering for the treatment of solid tumours","","Engineered bacterial therapeutics are promising candidates for treating solid cancers, yet pre-clinical efficacy often fails to translate to effective outcomes in humans. This review describes key features of in vitro eukaryotic:prokaryotic co-culture methods and explains how these platforms can probe bacterial behaviour. It outlines how co-cultures can inform iterative bacterial engineering to improve anti-cancer performance, bridging gaps left by costly and limited in vivo models.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/use-of-in-vitro-co-culture-models-to-inform-bacterial-engineering-for-the-treatment-of-solid-tumours/353990/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/use-of-in-vitro-co-culture-models-to-inform-bacterial-engineering-for-the-treatment-of-solid-tumours/353990.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do engineered bacterial therapeutics struggle to translate from pre-clinical models to humans?","Question",{"text":63,"@type":64},"Despite reducing tumour burden in pre-clinical models, only a limited number of bacterial therapeutics show strong efficacy in humans. The review suggests predictive power and pre-clinical study limitations contribute to this gap.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role can in vitro co-culture models play in bacterial therapeutic development?",{"text":68,"@type":64},"They provide a crucial tool to study cancer–bacteria interactions and to understand therapeutic bacterial behaviour in a controlled setting. This helps guide rational, iterative engineering before animal and clinical trials.",{"name":70,"@type":61,"acceptedAnswer":71},"Which bacteria are highlighted as tumour-targeting candidates?",{"text":72,"@type":64},"The review mentions genera such as Escherichia, Clostridium, Salmonella, Listeria and Streptococcus as capable of selectively colonising solid cancers in pre-clinical models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353990,1790215710,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","npj | biomedical innovations Review  \n\n| \u003Cbr>[https://doi.org/10.1038/s44385-026-00075-9](https://doi.org/10.1038/s44385-026-00075-9) |\n| --- |\n| Use of in vitro co-culture models to inform bacterial engineering for the treatment of solid tumours\u003Cbr> Check for updates |\n\nSara Foschini1, Josephine A. Wright1,2, Susan L. Woods1,2 & Rebekah de Nys1,2   \nEngineered bacterial therapeutics are emerging as promising candidates for the treatment of solid cancers. However, despite effectively reducing tumour burden in different pre-clinical models, these“smart bugs” are yet to convincingly translate this efﬁcacy to cancer treatment in humans. Here, we highlight key features of in vitro co-culture methods and how they can be used to investigate bacterial behaviour and guide the rational engineering of more effective anti-cancer bacterial therapeutics.  \nCancer is the leading cause of death worldwide1. By 2050, one in ﬁve people is estimated to develop cancer during their lifetime1,2. To alleviate the physical, emotional and economic burden posed by cancer3, better prevention and treatment tools are needed.  \nPatients with solid tumours rely primarily on standard of care treatment options such as surgery, chemotherapy and radiotherapy, used alone or in combination, depending on disease stage and tumour location4,5. Surgery is effective at early stages ofdisease in removing or reducing the size of solid tumours, but can lead to increased morbidity4,5. The delivery of radiation and systemic chemotherapy, while reasonably effective in reducing tumour burden6, can cause side effects by damaging healthy cells7 and tumour resistance, leading to treatment failure5,6,8.  \nOne promising strategy to address these challenges is the use of live bacterial therapeutics (LBTs), microorganisms that can prevent or treat disease in humans(excluding vaccines9, 10), to deliver anti-cancer payloads directly in the tumour microenvironment(TME)11, 12. This approach relies on the natural ability of certain bacteria to selectively colonize solid tumours over healthy tissues. Advancements in synthetic biology have enabled the genetic modiﬁcation of these tumour-homing bacteria to achieve anti-cancer payload biosynthesis in situ, thus improving on-target drug delivery11.  \nNumerous invivo pre-clinical studies have shown the potential ofthese“smart bugs” to function as tumour detectors13, 14 or to reduce tumour burden, including complete tumour regression when administered in combination with standard chemotherapy drugs15–17. However, despite showing potential in reducing tumour size in pre-clinical models14, 16–21, only a small number of bacterial therapeutics have progressed to clinical trials and those that have show limited efﬁcacy in humans12. This reduced antitumour response compared to pre-clinical studies may be due to the use of late stage and small patient cohorts, and limitations in pre-clinical study design22. This highlights the need to improve the predictive power of bacterial therapeutic screening methods prior to clinical trials.  \nIn vivo animal models, traditionally considered the “gold standard” for preclinical drug testing, enable assessment of therapeutic bacterial biodistribution, persistence and host responses. They can also offer insights into how therapeutic bacteria interact with host cells within the heterogeneous TME. However, they are expensive, time consuming, raise ethical concerns and do not comprehensively model human biology23–25. Thus, advanced in vitro eukaryotic:prokaryotic co-culture platforms represent a crucial tool in understanding cancer-bacteria interactions prior to animal and clinical trials. While other reviews have described how different co-culture models can be used to investigate eukaryotic:prokaryotic interactions to inform disease aetiology and progression26–30, here we examine how such models can inform iterative bacterial engineering for cancer therapeutics.  \nTumour-targeting bacteria  \nSeveral bacterial genera","cbCaidAu2wHfcTco","https://ap.wps.com/l/cbCaidAu2wHfcTco","pdf",1188214,"English","# Introduction\n# Live bacterial therapeutics for solid tumours\n# Limitations of in vivo models\n# Tumour-targeting bacteria\n# Synthetic biology to improve efficacy and safety","[{\"question\":\"Why do engineered bacterial therapeutics struggle to translate from pre-clinical models to humans?\",\"answer\":\"Despite reducing tumour burden in pre-clinical models, only a limited number of bacterial therapeutics show strong efficacy in humans. The review suggests predictive power and pre-clinical study limitations contribute to this gap.\"},{\"question\":\"What role can in vitro co-culture models play in bacterial therapeutic development?\",\"answer\":\"They provide a crucial tool to study cancer–bacteria interactions and to understand therapeutic bacterial behaviour in a controlled setting. This helps guide rational, iterative engineering before animal and clinical trials.\"},{\"question\":\"Which bacteria are highlighted as tumour-targeting candidates?\",\"answer\":\"The review mentions genera such as Escherichia, Clostridium, Salmonella, Listeria and Streptococcus as capable of selectively colonising solid cancers in pre-clinical models.\"}]","Use of in vitro co-culture models to inform bacterial engineering for the treatment of solid tumours | PDF",1790108374,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfa6395cebd6c7bbb80d1db6459453c2.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa0d5851ffb4dc6ef105422f5c7d1289.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f77e73b908f2dad599099d06ce88729.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20ceee6bf9f7b811c2e71197d12f6f45.webp",980,1301]